## **Xphozah (tenapanor) Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:			
important for the review (e	• •		n any additional documentation that is tion request). Information contained in		
			URGENT		
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:	DATE OF BIRTH:		
STREET ADDRESS:					
CITY:		STATE:	STATE: ZIP CODE:		
PATIENT INSURANCE ID N	UMBER:	'			
IF YOU ARE NOT THE PATIENT OR THE PRE FOLLOWING LINK: <u>PRIMETHERAPEUTICS.C</u>	SCRIBER, YOU WILL NEED TO SUBMIT A PHI DISC	CLOSURE AUTHORIZATION FORE	ALLERGIES:		
AUTHORIZED REPRESENTA	TIVE'S PHONE NUMBER:				
PRESCRIBER INFORMATION	N				
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:		
STREET ADDRESS:					
CITY:		STATE:	STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT	OFFICE CONTACT PERSON:		
		1			
MEDICATION OR MEDICA	L DISPENSING INFORMATION				
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILL	QUANTITY:		
NEW THERAPY DURATION OF THERAPY (S	RENEWAL PECIFIC DATES):	IF RENEWAL: DAT	E THERAPY INITIATED:		

Prime THERAPEUTICS\*

Continued on next page

## **Xphozah (tenapanor) Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
□ Post-gastric bypass surgery		100 201	
□ Stage 3 to 6 chronic kidney disease (CKD	)		
□ Other diagnosis:	ICD-10 Code(s):		
<b>3. REQUIRED CLINICAL INFORMATION</b> PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A	
Is patient going to be using drug in a d	clinical trial?   Yes   No		
Is patient receiving dialysis? ☐ Yes ☐	No		
Has the patient had a trial and inadeq ☐ Yes ☐ No Please provide documen	uate response or intolerance to calcium tation.	acetate tablets or capsules?	
Has the patient had a trial and inadeq Please provide documentation.	uate response or intolerance to Fosrence	ol (lanthanum carbonate)? □ Yes □ No	
Has the patient had a trial and inadeq Please provide documentation.	uate response or intolerance to Renage	l (sevelamer hcl)? □ Yes □ No	
Has the patient had a trial and inadeq Please provide documentation.	uate response or intolerance to Renvela	a(sevelamer carbonate)?   Yes   No	
Has the patient had a trial and inadeq Please provide documentation.	uate response or intolerance to Auryxia	(ferric citrate)? 🗆 Yes 🗆 No	
<ul> <li>patient is not being treat</li> <li>Parathyroid hormone (PTH) les</li> <li>with corrected calcium levels of</li> </ul>	uct greater than 55 mg2/dL2 greater than or equal to 9.5 mg/dL (or r ss than 150 pg/ml (or less than 2 times t	he upper limit of normal) in a patient	



## **Xphozah (tenapanor) Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?		
Please note: Not all drugs/diagnosis are covere information is received.	ed on all plans. This request may be denied unless all required	
ATTESTATION: I attest the information provide	ed is true and accurate to the best of my knowledge. I understand that designees may perform a routine audit and request the medical f the information reported on this form.	
Prescriber Signature or Electronic I.D. Verifica	ntion: Date:	
you are not the intended recipient, you are hereby notifie	ng this transmission contain confidential health information that is legally privileged. If ed that any disclosure, copying, distribution, or action taken in reliance on the contents eived this information in error, please notify the sender immediately (via return FAX) nents.	

**FAX THIS FORM TO:** 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909

